Cargando…

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients

Background: The MeroRisk-calculator, an easy-to-use tool to determine the risk of meropenem target non-attainment after standard dosing (1000 mg; q8h), uses a patient’s creatinine clearance and the minimum inhibitory concentration (MIC) of the pathogen. In clinical practice, however, the MIC is rare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liebchen, Uwe, Klose, Marian, Paal, Michael, Vogeser, Michael, Zoller, Michael, Schroeder, Ines, Schmitt, Lisa, Huisinga, Wilhelm, Michelet, Robin, Zander, Johannes, Scharf, Christina, Weinelt, Ferdinand A., Kloft, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074046/ https://www.ncbi.nlm.nih.gov/pubmed/33924047 http://dx.doi.org/10.3390/antibiotics10040468

Ejemplares similares

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study
por: Ehmann, Lisa, et al.
Publicado: (2017)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
por: Scharf, Christina, et al.
Publicado: (2020)

The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body
por: Liebchen, Uwe, et al.
Publicado: (2021)

Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
por: Scharf, Christina, et al.
Publicado: (2022)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome
por: Scharf, Christina, et al.
Publicado: (2020)

Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
por: Kallee, Simon, et al.
Publicado: (2022)

Therapeutic drug monitoring-guided high dose meropenem therapy of a multidrug resistant Acinetobacter baumannii - A case report
por: Liebchen, U., et al.
Publicado: (2019)

Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools
por: Weinelt, Ferdinand Anton, et al.
Publicado: (2022)

Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies
por: Germovsek, Eva, et al.
Publicado: (2018)

Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis
por: Scharf, Christina, et al.
Publicado: (2021)

Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study
por: Liebchen, Uwe, et al.
Publicado: (2021)

Can the cytokine adsorber CytoSorb(®) help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis
por: Scharf, Christina, et al.
Publicado: (2021)

Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial
por: Lutsar, Irja, et al.
Publicado: (2020)

Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
por: Scharf, Christina, et al.
Publicado: (2021)

The cytokine adsorber Cytosorb® does not reduce ammonia concentrations in critically ill patients with liver failure
por: Liebchen, Uwe, et al.
Publicado: (2023)

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing—A Translational Example for Intensive Care Units
por: Weinelt, Ferdinand Anton, et al.
Publicado: (2021)

Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
por: Habler, Katharina, et al.
Publicado: (2021)

Nuestro mero mole : breve historia de la comida mexicana
por: Flores y Escalante, Jesús
Publicado: (2013)

Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study
por: Greimel, Antonia, et al.
Publicado: (2023)

Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients
por: Busse, David, et al.
Publicado: (2021)

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
por: Chiriac, Ute, et al.
Publicado: (2023)

Del mero corazón. Chulas fronteras (videograbación)
Publicado: (1980)

182. Piperacillin/tazobactam (P/T) versus meropenem (Mero) for treatment of extended-spectrum beta-lactamase (ESBL)-producing E.coli and K. pneumoniae bloodstream infections (BSIs)
por: Cox, Alexandra L, et al.
Publicado: (2023)

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics
por: Busse, David, et al.
Publicado: (2021)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Was ist neu … in der Behandlung von invasiven Mykosen. COVID-19-assoziierte pulmonale Aspergillose
por: Scharf, Christina, et al.
Publicado: (2021)

CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm
por: Acevedo, Alice-Christin, et al.
Publicado: (2021)

Digestive enzymes of fungal origin as a relevant cause of false positive Aspergillus antigen testing in intensive care unit patients
por: Schroeder, Ines, et al.
Publicado: (2020)

The effect of cytosorb® application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis
por: Gräfe, Caroline, et al.
Publicado: (2023)

Draft Genome Sequence of Persistent Klebsiella grimontii AT013-Mero-001, Isolated from Human Feces
por: Bühler, Sarah, et al.
Publicado: (2021)

Quantification of Ploidy in Proteobacteria Revealed the Existence of Monoploid, (Mero-)Oligoploid and Polyploid Species
por: Pecoraro, Vito, et al.
Publicado: (2011)

Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data
por: Kluwe, Franziska, et al.
Publicado: (2023)

Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study
por: Zander, Johannes, et al.
Publicado: (2016)

Estimation of inter-laboratory reference change values from external quality assessment data
por: Paal, Michael, et al.
Publicado: (2021)

Rigidez Aórtica por Ressonância Magnética Cardíaca: Ferramenta Prognóstica ou Mero Espectador?
por: Câmara, Sérgio Figueiredo, et al.
Publicado: (2022)

2560. Individual Meropenem Epithelial Lining Fluid and Plasma PK/PD Target Attainment in Patients with Pneumonia
por: Rohani, Roxane, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bhg7n3hvht8n1o3q7kv3gbtkv3